Published in Psychol Aging on December 01, 1991
Memory systems do not divide on consciousness: Reinterpreting memory in terms of activation and binding. Psychol Bull (2009) 1.06
Neuroanatomical and cognitive mediators of age-related differences in perceptual priming and learning. Neuropsychology (2009) 0.81
Age-related changes in the cerebral substrates of cognitive procedural learning. Hum Brain Mapp (2009) 0.76
The mismeasure of memory: when retrieval fluency is misleading as a metamnemonic index. J Exp Psychol Gen (1998) 1.91
Engineered chimeric streptavidin tetramers as novel tools for bioseparations and drug delivery. Biotechnology (N Y) (1995) 1.78
The cue-familiarity heuristic in metacognition. J Exp Psychol Learn Mem Cogn (1993) 1.42
An NMDA intervention strategy in schizophrenia with "low-dose" milacemide. Clin Neuropharmacol (1991) 1.41
Aging and qualitative characteristics of memories for perceived and imagined complex events. Psychol Aging (1990) 1.39
Aging and source monitoring. Psychol Aging (1989) 1.39
Effect of visual cues, vital signs, and protocols on triage: a prospective randomized crossover trial. Ann Emerg Med (1998) 1.33
Electrospray mass spectrometric investigation of the chaperone SecB. Protein Sci (1996) 1.05
A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol (1989) 0.99
A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol (2001) 0.98
Clock drawing in the screening assessment of cognitive impairment in an ambulatory care setting: a preliminary report. Gen Hosp Psychiatry (1992) 0.90
Screening derivatized peptide libraries for tight binding inhibitors to carbonic anhydrase II by electrospray ionization-mass spectrometry. J Med Chem (1996) 0.89
Correlation between antisaccade and Wisconsin Card Sorting Test performance in schizophrenia. Am J Psychiatry (1993) 0.87
Methylene blue adjuvant therapy of schizophrenia. Clin Neuropharmacol (1997) 0.85
The looming maladaptive style: anxiety, danger, and schematic processing. J Pers Soc Psychol (2000) 0.85
The alcohol facilitation effect on memory: a dose-response study. Psychopharmacology (Berl) (1981) 0.85
Bio-affinity characterization mass spectrometry. Rapid Commun Mass Spectrom (1995) 0.84
Subtype diagnosis in schizophrenia and its relation to neuropsychological and computerized tomography measures. Biol Psychiatry (1991) 0.81
Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin Neuropharmacol (2001) 0.80
Data-driven and conceptually driven processes in partial-word identification and recognition. J Exp Psychol Learn Mem Cogn (1988) 0.78
Visual scanning of faces correlates with schizophrenia symptomatology. Prog Neuropsychopharmacol Biol Psychiatry (1998) 0.77
Effect of a low-tryptophan diet as an adjuvant to conventional neuroleptic therapy in schizophrenia. Clin Neuropharmacol (1992) 0.76
Stress and a glycinergic intervention interact in the modulation of MK-801-elicited mouse popping behavior. Pharmacol Biochem Behav (1999) 0.76
Generation and elaboration in older adults. Exp Aging Res (1989) 0.76
An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy. Clin Neuropharmacol (1990) 0.76
Frontal cortical atrophy and negative symptoms in patients with chronic alcohol dependence. J Neuropsychiatry Clin Neurosci (1997) 0.75
Nefazodone in the adjunctive therapy of schizophrenia: an open-label exploratory study. Clin Neuropharmacol (2001) 0.75
An intake service in a private psychiatric hospital. Hosp Community Psychiatry (1966) 0.75
Diving reflex in tachyarrhythmia. Arch Intern Med (1980) 0.75
L-tyrosine pharmacotherapy of schizophrenia: preliminary data. Clin Neuropharmacol (1994) 0.75
Letter to the editor. Science (1972) 0.75